Antibody Drug Slows Disability Progression in Advanced Multiple Sclerosis
Phase III results show that ocrelizumab could benefit a much larger population, including multiple sclerosis patients who are older or at more advanced stages o...
Phase III results show that ocrelizumab could benefit a much larger population, including multiple sclerosis patients who are older or at more advanced stages of the disease. The post Antibody Drug Slows Disability Progression in Advanced Multiple Sclerosis appeared first on Inside Precision Medicine .